Physician profile
Michael E Mcmurry
NPI 1275638058
$908.59
in general payments reported to CMS, 2019-2025
12 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $193 · 2023: $184 · 2024: $295 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $715.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $123.35 | 2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $123.00 | 2024 | |
| Ani Pharmaceuticals, INC. | $122.79 | 2023 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $122.79 | 2025 | Rexulti |
| Horizon Therapeutics Plc | $98.69 | 2021 | |
| Alexion Pharmaceuticals, INC. | $94.29 | 2021 | |
| Baxter Healthcare | $48.67 | 2024 | Renal - Pd |
| Fresenius USA Marketing, INC. | $45.97 | 2023-2025 | Optiflux, Velphoro, Korsuva |
| Novo Nordisk INC | $40.00 | 2023 | |
| Mallinckrodt Hospital Products INC. | $35.67 | 2025 | Acthar |
| Soleno Therapeutics, INC. | $33.08 | 2025 | Vykat Xr |
| Inogen, INC. | $20.29 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcmurry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.